Sono-photodynamic therapy (SPDT) utilises both sound and light frequencies to damage and destroy tumors. A sensitising agent primes the tumor cells to specific frequencies, but has no effect on regular, healthy cells.

Administration of SPDT through localised and whole body routes then causes a reaction within the sensitised tumor cells, which results in formation of reactive oxygen species (ROS), destroying the tumor mass. The therapy produces minimal side effects and does not damage surrounding tissues. The SPDT clinical trial treats men with prostate cancer who have not responded to previous treatment, and may, in the future offer a further treatment option for patients who have failed other therapies.

PDT is conducted as part of a clinical trial - NIIM is currently not accepting participants